SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Actuate Therapeutics to Present Preclinical Elraglusib Data at ENA 2026

The company says it will present preclinical data on oral elraglusib in advanced melanoma models.

ACTU

Related stories